THE UK Medicines and
Healthcare products Regulatory
Agency (MHRA) has advised health
professionals to closely observe the
current contraindications and
monitoring requirements for
rosiglitazone (Avandia).
The MHRA says there’s currently
an ongoing Europe-wide review of
the risks and benefits of the
diabetes medication due to new
data which raises concern about an
increased risk of cardiovascular
adverse effects.
Patients are also being reminded
of the importance of attending
routine appointments to monitor
their diabetic care.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jul 10
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.